Risk stratification for sudden death: Should we only consider ejection fraction?;La stratificazione del rischio di morte improvvisa: dobbiamo considerare solo la frazione di eiezione?

Giornale Italiano di Cardiologia

Volumn 9, Issue 10 SUPPL.1, 2008, Pages

  Paolucci, Marco ^a   Cattafi, Giuseppe ^a   Magenta, Giovanni ^a   Vecchi, Maria Rita ^a   Schirru, Milena ^a   Lunati, Maurizio ^a  

^a AO Niguarda Ca' Granda   (Italy)

Author keywords

Ejection fraction; Implantable cardioverterdefibrillator; Sudden cardiac death

Indexed keywords

ARTICLE; DEFIBRILLATOR; HEART CONTRACTION; HEART STROKE VOLUME; HUMAN; PHYSIOLOGY; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STANDARD; SUDDEN DEATH;

DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; MYOCARDIAL CONTRACTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STROKE VOLUME;

EID: 59849116750     PISSN: 18276806     EISSN: 19726481     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Zipes DP, Libby P, Bonow R, Braunwald E, eds. Heart disease: a textbook of cardiovascular medicine. 7th edition. Philadelphia, PA: WB Saunders, 2005: 865-908.
2. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22: 1374-450.
3. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, Stricker BH, Sturkenboom MC. The incidence of sudden cardiac death in the general population. J Clin Epidemiol 2004; 57: 98-102.
4. Pepine CJ, Morganroth J, McDonald JT, Gottlieb SO. Sudden death during ambulatory electrocardiographic monitoring. Am J Cardiol 1991; 68: 785-8.
5. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117: 151-9.
6. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345: 1473-82.
7. Cabell CH, Heidenreich PA, Chu VH, et al. Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. Am Heart J 2004; 147: 582-6.
8. Gould PA, Khran AD, for the Canadian Heart Rhythm Society Working Group on Device Advisories. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA 2006; 295: 1907-11.
9. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993; 119: 1187-97.
10. Demirovic J, Myerburg RJ. Epidemiology of sudden coronary death: an overview. Prog Cardiovasc Dis 1994; 37: 39-48.
11. De Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30: 1500-5.
12. Ruberman W, Weinblatt E, Goldberg JD, Frank CW, Chaudhary BS, Shapiro S. Ventricular premature complexes and sudden death after myocardial infarction. Circulation 1981; 64: 297-305.
13. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341: 1882-90.
14. Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 1993; 21: 110-6.
15. Stevenson WE, Stevenson LW, Middlekauff HR, Saxon LA. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation 1993; 88: 2953-61.
16. Maron BJ, Shen W, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365-73.
17. Schwartz PJ. The long QT syndrome. Curr Probl Cardiol 1997; 22: 297-351.
18. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20: 1391-6.
19. Centers for Disease Control and Prevention (CDC). Statespecific mortality from sudden cardiac death -United States, 1999. MMWR Morb Mortal Wkly Rep 2002; 51: 123-6.
20. Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol 1998; 32: 245-51.
21. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984; 69: 250-8.
22. Julian DG, Camm AJ, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349: 667-74.
23. Colucci WS. Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN). Am J Cardiol 2004; 93 (9A): 13B-16B.
24. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-6.
25. Singh SN, Fletcher RD, Fisher S, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77-82.
26. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344: 493-8.
27. Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G. Mechanism of death in heart failure. The VHeFT VA Cooperative Studies Group. Circulation 1993; 87 (6 Suppl): VI24-VI31.
28. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
29. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.
30. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
31. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death -executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006; 27: 2099-140.
32. Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 1993; 87: 312-22.
33. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJ. Out-of-hospital cardiac arrest-the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 2003; 24: 1204-9.
34. Solomon SD, Zelenkofske S, McMurray JJ, for the Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352: 2581-8.
35. Grimm W, Christ M, Bach J, Muller HH, Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy. Circulation 2003; 108: 2883-91.
36. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-40.
37. Moss AJ, Zareba W, Hall WJ, et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-83.
38. Bardy GH, Lee KL, Mark DB, et al, for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-37.
39. Kadish A, Dyer A, Daubert JP, et al, for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-8.
40. Bristow MR, Saxon LA, Boehmer J, et al, for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50.
41. Al-Khatib SM, Sanders GD, Mark DB, et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J 2005; 149: 1020-34.
42. Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 2006; 47: 1161-6.
43. Daubert JP, Zareba W, Cannom DS, et al, for the MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008; 51: 1357-65.
44. Saxon LA, Bristow MR, Boehmer J, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006; 114: 2766-72.
45. Camm J, Klein H, Nisam S. The cost of implantable defibrillators: perceptions and reality. Eur Heart J 2007; 28: 392-7.
46. Huikuri HV, Tapanainen JM, Lindgren K, et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2003; 42: 652-8.
47. Buxton AE, Lee KL, Hafley GE, et al, for the MUSTT Investigators. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol 2007; 50: 1150-7.